The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 14, 2019

Filed:

Sep. 26, 2016
Applicant:

Expression Pathology, Inc., Rockville, MD (US);

Inventors:

Daniel Catenacci, Chicago, IL (US);

Todd Hembrough, Gaithersburg, MD (US);

Fabiola Cecchi, Washington, DC (US);

Wei-Li Liao, Herndon, VA (US);

Assignees:

Expression Pathology, Inc., Rockville, MD (US);

The University Of Chicago, Chicago, IL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57446 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/22 (2013.01); C07K 16/2863 (2013.01); G01N 2333/4753 (2013.01); G01N 2333/71 (2013.01); G01N 2333/82 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods are provided for treating a gastric cancer patient. A specific Met fragment peptide is precisely quantitated by SRM-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. If the Met peptide is below the reference level a second therapeutic regimen is used to treat the patient whereas if the Met peptide is above the reference level then a first therapeutic regimen combining, for example, the second regimen with one or more Met inhibitor therapeutic agents may be used to treat the patient.


Find Patent Forward Citations

Loading…